O Shaughnessy Asset Management LLC Has $138,000 Stake in Certara, Inc. (NASDAQ:CERT)

O Shaughnessy Asset Management LLC increased its holdings in shares of Certara, Inc. (NASDAQ:CERT) by 20.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,943 shares of the company’s stock after acquiring an additional 2,202 shares during the period. O Shaughnessy Asset Management LLC’s holdings in Certara were worth $138,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of CERT. Venturi Wealth Management LLC increased its stake in shares of Certara by 839.1% in the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock valued at $30,000 after buying an additional 2,509 shares in the last quarter. Blue Trust Inc. lifted its position in shares of Certara by 20.9% during the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock worth $56,000 after purchasing an additional 822 shares in the last quarter. ANTIPODES PARTNERS Ltd grew its stake in shares of Certara by 204.7% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company’s stock valued at $58,000 after purchasing an additional 3,656 shares during the last quarter. KBC Group NV lifted its holdings in Certara by 64.1% during the 4th quarter. KBC Group NV now owns 7,998 shares of the company’s stock worth $85,000 after buying an additional 3,125 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in Certara by 442.2% in the 4th quarter. GAMMA Investing LLC now owns 8,421 shares of the company’s stock valued at $90,000 after buying an additional 6,868 shares during the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Stephens reaffirmed an “overweight” rating and set a $17.00 price target on shares of Certara in a research note on Thursday, February 27th. Robert W. Baird lifted their price target on shares of Certara from $9.00 to $13.00 and gave the stock a “neutral” rating in a research report on Friday. William Blair restated a “market perform” rating on shares of Certara in a report on Thursday, February 27th. Barclays lowered their target price on shares of Certara from $13.00 to $11.00 and set an “equal weight” rating for the company in a report on Thursday, April 10th. Finally, TD Cowen began coverage on Certara in a research report on Thursday, February 27th. They issued a “buy” rating and a $16.00 price target on the stock. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $15.50.

Certara Price Performance

Shares of CERT stock opened at $14.40 on Tuesday. The firm has a market capitalization of $2.33 billion, a price-to-earnings ratio of -72.00, a price-to-earnings-growth ratio of 9.29 and a beta of 1.64. Certara, Inc. has a 12-month low of $8.64 and a 12-month high of $17.94. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The firm has a fifty day moving average of $11.61 and a 200-day moving average of $11.39.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.